证券代码：688246 证券简称：嘉和美康 公告编号：2024-031 嘉和美康（北京）科技股份有限公司 2023 年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 25 | | --- | --- | | 普通股股东人数 | 25 | | 2、出席会议的股东所持有的表决权数量 | 63,720,056 | | 普通股股东所持有表决权数量 | 63,720,056 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的 | 46.3192 | | 比例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例 | 46.3192 | | （%） | | （四） 表决方式是否符合《公司法》及公司章程的规定，大会主持情况等。 （一） 股东大会召开的时间：2024 年 05 月 21 日 ...

Investment Rating - The report maintains a "Buy" rating for the company, expecting a relative performance increase of over 15% against the benchmark index within the next 6 to 12 months [4][18]. Core Insights - The company reported a significant improvement in Q1 2024 revenue, with a year-on-year growth rate of 14.0%, following a decline of 3.04% in 2023 [2][18]. - The net profit for Q1 2024 was a loss of 0.12 billion, contrasting with a net profit of 0.42 billion in 2023, which saw a decline of 37.53% [18]. - The company has increased its investment in medical AI, with a year-on-year growth of 28.38% in this area, indicating a strong focus on research and development [18]. Financial Summary - Revenue projections for the company are as follows: 2023 at 695 million, 2024E at 903 million, 2025E at 1,148 million, and 2026E at 1,447 million [3][18]. - Net profit forecasts are 42 million for 2023, 95 million for 2024E, 120 million for 2025E, and 160 million for 2026E, showing a recovery trend after a dip in 2023 [3][18]. - The company's earnings per share (EPS) are projected to increase from 0.31 in 2023 to 1.15 by 2026 [3][18]. Investment Highlights - The company has faced temporary performance pressure in 2023 due to macroeconomic changes and regulatory impacts on hospital procurement processes, but it is expected to recover with improved revenue growth in 2024 [18]. - The company has completed the development and training of its medical AI model, which supports various medical tasks, indicating a strong commitment to innovation and product development [18]. - Collaboration with partners in the medical AI field is expected to enhance the company's market position and product offerings [18].

华泰联合证券有限责任公司 关于嘉和美康（北京）科技股份有限公司 2023 年度持续督导跟踪报告 | 保荐机构名称：华泰联合证券有限责任公司 | 被保荐公司简称：嘉和美康 | | --- | --- | | 保荐代表人姓名：孔祥熙 | 联系电话：010-56839300 | | 保荐代表人姓名：王琛 | 联系电话：010-56839300 | 根据《证券法》《证券发行上市保荐业务管理办法》和《上海证券交易所科 创板股票上市规则》等有关法律、法规的规定，华泰联合证券有限责任公司（以 下简称"华泰联合证券"或"保荐机构"）作为嘉和美康（北京）科技股份有限 公司（以下简称"嘉和美康"、"公司"或"发行人"）首次公开发行股票的保 荐机构，对嘉和美康进行持续督导，并出具 2023 年度（以下简称"报告期"）持 续督导跟踪报告： 一、保荐机构和保荐代表人发现的问题及整改情况 二、重大风险事项 公司面临的风险因素主要包括： （一）核心竞争力风险 1、因技术升级导致的产品迭代风险 保荐机构核查发现，公司股东存在未能及时履行承诺的情形，具体如下： 公司股东咸宁市凯旋机会成长基金（有限合伙）（以下简称"凯旋成长"） 于公司首发上市 ...

证券代码：688246 证券简称：嘉和美康 嘉和美康（北京）科技股份有限公司 2023 年年度股东大会会议资料 2024 年 5 月 21 日 | 2023 年年度股东大会会议须知 | | | 2 | | --- | --- | --- | --- | | 2023 年年度股东大会会议议程 | | | 4 | | 2023 年年度股东大会会议议案 | | | 6 | | 议案一：关于公司 | 2023 | 年度董事会工作报告的议案 | 6 | | 议案二：关于公司 | 2023 | 年度财务决算报告的议案 | 7 | | 议案三：关于公司 | 2023 | 年度利润分配预案的议案 | 8 | | 议案四：关于公司 | 2023 | 年年度报告及摘要的议案 | 9 | | 议案五：关于公司 | 2024 | 年度董事薪酬的议案 | 10 | | 议案六：关于公司 | 2024 | 年度对外担保预计的议案 | 11 | | 议案七：关于公司 | 2023 | 年度监事会工作报告的议案 | 12 | | 议案八：关于公司 | 2024 | 年度监事薪酬的议案 | 13 | | | | 议案九：关于变更公司注册资本、 ...

证券代码：688246 证券简称：嘉和美康 嘉和美康（北京）科技股份有限公司投资者关系活动记录表 编号：2024-001 □特定对象调研 □分析师会议 投资者关系活 □媒体采访 业绩说明会 □新闻发布会 □路演活动 动类别 □现场参观 □其他 参与单位名称 华泰证券 范昳蕊 华泰证券 谢春生 及人员姓名 上海东方证券资产管理有限公司 王延飞 招商基金管理有限公司 陆文凯 招商基金管理有限公司 杨成 大成基金管理有限公司 杜聪 POWER PACIFIC INVESTMENT 周俊恺 ...

证券代码：688246 证券简称：嘉和美康 公告编号：2024-026 嘉和美康（北京）科技股份有限公司 股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 股东持股的基本情况 截至本公告披露日，嘉和美康（北京）科技股份有限公司（以下简称"嘉和 美康"或"公司"）股东苏州赛富璞鑫医疗健康产业投资中心（有限合伙）（以下 简称"赛富璞鑫"）持有公司股份 5,854,969 股，占公司股份总数的 4.23%。上述 股份为嘉和美康首次公开发行并上市前取得的股份，且已于 2022 年 12 月 14 日 起上市流通。 减持计划的主要内容 公司于 2024 年 5 月 6 日收到赛富璞鑫出具的《关于股东减持计划的告知 函》，因自身资金需求，股东赛富璞鑫计划根据市场情况拟通过集中竞价方式和 大宗交易方式减持其持有的公司股份合计不超过 2,770,846 股，即不超过公司总 股本的 2.00%。其中，通过集中竞价交易方式和大宗交易方式分别减持不超过 1,385,423 股，自本公告披露之日起 ...

证券代码：688246 证券简称：嘉和美康 公告编号：2024-027 公司于 2024 年 4 月 26 日召开第四届董事会第十七次会议，审议通过了《关 于变更回购公司股份用途的议案》，同意对回购公司股份的用途进行调整，本次回 购股份用途由"用于员工持股计划或股权激励"变更为"用于注销以减少注册资 本"。除该项内容修改外，回购方案中其他内容均不作变更。上述回购用途变更事 项尚需股东大会审议通过。 二、 回购股份的进展情况 根据《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关 规定，在回购股份期间，公司应当在每个月的前 3 个交易日内公告截至上月末的 回购进展情况。 嘉和美康（北京）科技股份有限公司 关于以集中竞价交易方式回购股份进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2023/8/23 | | | | | | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2023 8 日~2024 年 8 ...

Investment Rating - The report maintains a "Buy" rating for the company, with a target price of 25.44 CNY per share based on a 45x PE valuation for 2024 [5][36]. Core Views - The company's performance in 2023 was under pressure, primarily due to external regulatory impacts on hospital procurement activities, resulting in a revenue decline of 3.0% year-on-year to 700 million CNY and a net profit drop of 37.5% to 42.5 million CNY [2][11]. - External regulatory pressures have largely eased, leading to a recovery expectation for Q1 2024, where revenue increased by 14.0% year-on-year to 120 million CNY, and net loss narrowed by 47.7% compared to the previous year [3][21]. - The company is actively upgrading its electronic medical record (EMR) and data center products, achieving significant progress in specialized EMR, with notable revenue growth in emergency medical platforms [28][29]. - The company is exploring AI applications in healthcare, having developed a medical model that supports nearly 20 medical tasks and has become the largest shareholder of Ande Medical Intelligence [29][32]. Financial Performance Summary - **2023 Financial Data**: - Revenue: 700 million CNY, down 3.0% YoY - Net Profit: 42.5 million CNY, down 37.5% YoY - Gross Margin: 51.8%, up 0.7 percentage points YoY [11][21]. - **2024 Q1 Financial Data**: - Revenue: 120 million CNY, up 14.0% YoY - Net Loss: 11.85 million CNY, loss narrowed by 47.7% YoY - Gross Margin: 47.2%, up 2.2 percentage points YoY [3][17]. Revenue and Profit Forecast - The company forecasts revenues of 840 million CNY, 1.0 billion CNY, and 1.19 billion CNY for 2024, 2025, and 2026, respectively, with net profits expected to be 80 million CNY, 130 million CNY, and 170 million CNY for the same years [32][35]. - The earnings per share (EPS) are projected to be 0.57 CNY, 0.93 CNY, and 1.24 CNY for 2024, 2025, and 2026, respectively [35]. Product and Market Development - The company has made significant advancements in its EMR products, assisting 31 medical institutions in achieving high-level certifications by the end of 2023, and has upgraded its emergency medical platform, generating substantial revenue growth [28][29]. - The company is also focusing on AI in healthcare, with a strategic investment in Ande Medical Intelligence, enhancing its capabilities in medical imaging and clinical decision support [29][32]. Cost and Margin Outlook - The gross margin is expected to remain high and gradually increase, projected at 52.6%, 53.3%, and 53.6% for 2024, 2025, and 2026, respectively [33]. - The company anticipates a decrease in sales expense ratio due to improved revenue, with projections of 15.0%, 14.5%, and 14.0% for the next three years [34].

Investment Rating - The report maintains a "Recommendation" rating for the company, with a target price of 31.2 CNY based on a projected 40x PE for 2024 [9][11]. Core Insights - The company experienced a slight decline in revenue in 2023, with total revenue of 695 million CNY, down 3.04% year-on-year, and a net profit of 42 million CNY, down 37.53% year-on-year. However, Q1 2024 showed a recovery with revenue of 123 million CNY, up 14% year-on-year, and a reduced net loss of 12 million CNY, narrowing by 47.70% [9][11]. - The electronic medical record (EMR) platform revenue remained stable, generating 208 million CNY, while specialized EMR solutions saw significant growth, with revenue increasing threefold to 18 million CNY [11]. - The company is a leader in the medical big data sector, with a market share of 8.8% in 2022, and has expanded its product offerings to county-level medical institutions [11]. - The company has developed a medical large model leveraging AIGC technology, which supports various medical tasks and is expected to enhance product value [11]. Financial Summary - For 2023, the company reported total revenue of 695 million CNY and a net profit of 42 million CNY. Projections for 2024-2026 indicate revenue growth to 869 million CNY, 1.06 billion CNY, and 1.27 billion CNY, respectively, with net profits expected to reach 108 million CNY, 151 million CNY, and 191 million CNY [11][12]. - The report highlights an increase in operating expenses, with sales, management, and R&D expense ratios at 15.14%, 11.96%, and 20.85%, respectively [11]. - The company’s earnings per share (EPS) are projected to grow from 0.78 CNY in 2024 to 1.38 CNY in 2026, reflecting a positive outlook despite short-term challenges [11].